Add description, images, menus and links to your mega menu
A column with no settings can be used as a spacer
Link to your collections, sales and even external links
Add up to five columns
Add description, images, menus and links to your mega menu
A column with no settings can be used as a spacer
Link to your collections, sales and even external links
Add up to five columns
November 04, 2022 2 min read
There is growing evidence that CBD has a calming effect on the central nervous system. Its reputation as an anxiolytic appears justified. There has been much study in particular on anxiety and in sleep, both CNS-mediated, but surprisingly, not together. The literature has not yet explored CBD in sleep problems that are related to stress. Until now.
Results of a retrospective multi-university study in Colorado have been recently published (Perm J. 2019;23:18-041. doi: 10.7812/TPP/18-041), on the question of whether CBD improves sleep in a clinical population under treatment for anxiety. It was undertaken as a monthly clinical chart review of 103 adult patients.
Most patients reviewed were given 25 mg of oral CBD a day, in capsule form, a rate usually much lower than that reported in clinical literature. In cases of heavy anxiety, the dosing was every morning, after breakfast; in patients for whom sleep complaints predominated, dosing was every evening, after dinner. A few patients were given 50 mg or 75 mg. One patient with a schizoaffective disorder and a history of trauma received gradually increasing dosages to 175 mg daily. Dosing in the end reflected individual healthcare professionals’ clinical judgment. Sleep and anxiety scores were assessed with validated instruments at baseline and after CBD treatment. This was open-label treatment, and there was no comparison group. Most patients were also receiving psychiatric medications and receiving concomitant mental health services, such as counseling.
In the final sample, of 72 patients, anxiety scores decreased in the first month in 57 patients (79.2%) and remained so for the duration of the study. Sleep scores improved in the first month in 48 patients (66.7%), though these scores fluctuated. A secondary endpoint was safety. In this population, CBD was well tolerated in all but 3 cases.
PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis but without residual cannabinoids like THC or any of the impurities or chemicals associated with plant-derived production processes. Our molecular assembly technique, that synthesizes CBD from aromatic terpenes instead of cannabis, assures you the food and pharmaceutical-grade quality that you need for quality-conscious customers. If you are interested in PureForm CBD™ or want to partner on any other of the 140+ known cannabinoids, please contact Damian Peters at 310-666-4869, or emailinfo@pureformglobal.com.
The foregoing is a report on trends and developments in the cannabinoid industry. No product described herein is intended to diagnose, treat, cure or prevent any disease or syndrome.
Promotions, new products and sales. Directly to your inbox.